Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-31
2006-10-31
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S443000, C514S444000, C514S461000, C514S469000, C514S543000, C514S571000, C549S058000, C549S079000, C549S469000, C549S501000, C560S017000, C560S061000, C562S468000
Reexamination Certificate
active
07129268
ABSTRACT:
Novel compounds of the general formula (I),wherein Ar, R1, R2, X1, X2, Y1, Y, and Z are as defined in the specification, the use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds and methods of treatment employing these compounds and compositions. The present compounds may be useful in the treatment and/or prevention of conditions mediated by Peroxisome Proliferator-Activated Receptors (PPAR), in particular the PPARδ subtype.
REFERENCES:
patent: 4148915 (1979-04-01), Thuillier et al.
patent: 5919793 (1999-07-01), Brown et al.
patent: 6555577 (2003-04-01), Mogensen et al.
patent: 6972294 (2005-12-01), Murray et al.
patent: 2004/0024034 (2004-02-01), Brooks et al.
patent: 2004/0143006 (2004-07-01), Jeppesen et al.
patent: 2005/0080115 (2005-04-01), Jeppesen et al.
patent: WO 97/27847 (1997-08-01), None
patent: WO 97/27857 (1997-08-01), None
patent: WO 97/28115 (1997-08-01), None
patent: WO 97/28137 (1997-08-01), None
patent: WO 97/28149 (1997-08-01), None
patent: WO 97/48674 (1997-12-01), None
patent: WO 98/27974 (1998-07-01), None
patent: WO 99/04815 (1999-02-01), None
patent: WO 200063153 (2000-10-01), None
patent: WO 01/00603 (2001-01-01), None
patent: WO 01/025181 (2001-04-01), None
patent: WO 01/79197 (2001-10-01), None
patent: WO 200179150 (2001-10-01), None
patent: WO 02/14291 (2002-02-01), None
patent: WO 02/059098 (2002-08-01), None
patent: WO 2004037776 (2004-05-01), None
Tiikkainen, M., et al., “Effects of Rosiglitazone and Metformin on Liver Fat Content, Hepatic Insulin Resistance, Insulin Clearance, and Gene Expression in Adipose Tissue in Patients with Type 2 Diabetes,” Diabetes, vol. 53, pp. 2169-2176 (Aug. 2004).
Willson, T., et al., “The PPARs: From Orphan Receptors to Drug Discovery,” J. Med. Chem., vol. 43(4), pp. 527-550 (Feb. 2000), at p. 527, col. 1, lines 25-28.
Kersten, S., et al., “Roles of PPARs in health and disease,” Nature, vol. 405, pp. 421-424 (May 2000), at p. 421, col. 1, lines 14-19, et seq.
Kaplan, F., et al., “PPARs, Insulin Resistance and Type 2 Diabetes,” J. Cardiovasc. Risk, vol. 8(4), pp. 211-217 (Aug. 2001), at p. 213, col. 1, lines 23-34 and 37-52.
Berger, J. and Wagner, J., “Physiological and Therapeutic Roles of Peroxisome Proliferator-Activated Receptors,” Diabetes Technology & Therapeutics, vol. 4(2), pp. 163-174 (2002), at p. 166 (Table 1) and p. 167, col. 1, lines 24, et seq.
Fruchart, J., “PPAR and Cardiovascular Risk: Overview,” J. Cardiovasc. Risk, vol. 8(4), pp. 185-186 (Aug. 2001), at p. 185, lines 13-20.
Jones, B., “Peroxisome Proliferative-Activated Receptor (PPAR) Modulators: Diabetes and Beyond,” Medicinal Research Reviews, vol. 21(6), pp. 540-552 (Nov. 2001), at p. 541, lines 7-30 and p. 547 (Table II).
Vamecq, J. and Latruffe, N., “Medical significance of peroxisome proliferator-activated receptors,” The Lancet, vol. 354, pp. 141-148 (Jul. 10, 1999), at p. 146.
Torra, I., et al., “Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice,” Curr. Opin. Lipidol., vol. 12, pp. 245-254 (2001), at p. 250, col. 2, lines 9-18 and p. 245, lines 5-7.
Michalik, L., and Wahli, W., “Peroxisome proliferator-activated receptors: three isotypes for a multitude of functions,” Curr. Opin. Biotechnology, vol. 10, pp. 564-570 (1999), at p. 565, lines 17-21 and Fig. 1.
Miller, A., and Etgen, G., “Novel peroxisome proliferator-activated receptor ligands for type 2 diabetes and the metabolic syndrome,” Expert Opin. Investig. Drugs, vol. 12(9), pp. 1489-1500 (2003), at p. 1490, col. 2, lines 2-21 and p. 1492, 17-48.
Wahli, W., “Peroxisome Proliferator-Activated Receptors (PPARs): from metabolic control to epidermal wound healing,” Swiss Med. Weekly, vol. 132, pp. 83-91 (2002), at p. 86, col. 1, lines 4-27.
Everett, L., et al., “The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease,” Liver, vol. 20, pp. 191-199 (2000), at p. 191, lines 1-14.
Mital, A., “PPARs: Nuclear Receptors for Antidiabetics,” CRIPS, vol. 3(1), pp. 5-8 (Jan.-Mar. 2002), at p. 8, col. 1, lines 4-14.
Liu, K., et al., “Identification of a Series of PPAR γ/δ Dual Agonists via Solid-Phase Parallel Synthesis,” Bioorg. Med. Chem. Lett., vol. 11, pp. 2959-2962 (Nov. 2001), at p. 2959, col. 2, lines 10-12.
Kaplan et al., “PPARs Insulin Resistance and Type 2 Diabetes,” J. Cardiovasc. Risk, vol. 8(4), pp. 211-217 (Aug. 2001), especially p. 213, col. 1, lines 23-34 and 37-52.
Torra et al.,“PPARs: from transcriptional control to clinical practice,” Curr. Opin. Lipidol., vol. 12, pp. 245-254 (2001), especially p. 250, col. 2, lines 9-18 and p. 245, lines 5-7.
Berger et al., Journal of Biological Chemistry, vol. 274, No. 10, pp. 6718-6725 (1999).
Leibowitz et al., FEBS Letters, vol. 473, pp. 333-336 (2000).
Oliver et al, Proceedings of the National Academy of Sciences of the USA, vol. 98, 5306-5311 (2001).
Muoio et al., Journal of Biological Chemistry, vol. 277, No. 29, pp. 26089-26097 (2002).
Havranek Miroslav
Jeppesen Lone
Mogensen John Patrick
Pettersson Ingrid
Pihera Pavel
Bork Richard W.
Chung Susannah L.
Green Reza
Novo Nordisk A S
Saeed Kamal A.
LandOfFree
Peroxisome proliferator activated receptor-active arylene... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peroxisome proliferator activated receptor-active arylene..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peroxisome proliferator activated receptor-active arylene... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3716454